SEPTEMBER

10

2019

SEPTEMBER

10

2019

September 10th, 2019 – Atlanta, Georgia U.S.A.

SAH and Neutron Therapeutics Inc. enter into agreementto develop Boron Neutron Capture Therapy

SAH Global and neutron Therapeutics Inc (NTI) have entered into agreement to develop Boron Neutron Capture Therapy (BNCT).

BNCT is a powerful alternative to traditional radiotherapy and proton therapy, with the ability to deliver targeted radiation to cancer cells while sparing surrounding healthy tissue.

In BNCT treatment, a boron carrier compound injected into the blood stream is selectively absorbed by tumor cells. The tumor is irradiated with a therapeutic neutron beam. The neutron beam reacts with the boron, while safely passing through surrounding tissue. The boron reaction produces highly excited alpha particles of very short path lengths (5–9 µm) that destroy tumor cells from the inside with minimal effect on immediately surrounding tissue. BNCT has successfully been used to treat cancer patients in cases where other treatment options have been exhausted. Typical BNCT therapies utilize two patient treatments vs. dozens for traditional radiotherapy, reducing stress on patients while enhancing treatment center efficiency and patient throughput.

NTI’s unique and patented neutron source replaces the nuclear reactor in traditional BNCT research platforms. Engineered from the ground up for high reliability and ease of maintenance, NTI’s platform can enable the widespread adoption of BNCT.

SAH is committed to the development and introduction of state-of-the-art cancer treatment technology in the Middle-East, Africa, Latin America, and Asia.

Through this agreement, SAH and NTI will collaborate to secure FDA and CE marks, and to introduce BNCT as a treatment for cancer patients worldwide.

About SAH Global

Strategic Alliance Holdings Global, LLC (“SAH Global”), is a holding company founded in 2005 to establish highly specialized projects in areas such as healthcare. SAH Global has actively pioneered the effort to bring vital cancer treatment solutions to the Middle East. SAH Global believes in building a strong sustainable society, and as such, will leverage the success of its global ventures to make long-term contributions to the community, promote the growth of their employees, and help create a greener environment.

About SAH Care

SAH Care was established to ensure that patients from across the world can have access to the best treatments available. We work tirelessly with local physicians and a global network of leading healthcare providers to bring excellent quality cancer care to our patients. Our team, partners, and supporters share a commitment to improve the delivery of high-quality, patient-centric cancer care.
Through travel medicine, we have found a way to provide access to advanced cancer care for those who live in areas where proton therapy centers are yet to be built. We believe that patients deserve to receive the most advanced cancer treatment in the world today despite geographic boundaries and limitations. The SAH Care team provides this compassionate, comprehensive care to patients wherever they live.

About NTI

Neutron Therapeutics is a Boston-area medical equipment company founded in 2015 by New Zealander, Bill Buckley. The mission of NTI is to provide innovative technology solutions that will enable BNCT to realize its maximum potential in the treatment of difficult cancers.

The Neutron Therapeutics neutron source is not approved for commercial or clinical use by the FDA or EMA or other regulatory body.

AUGUST

9

2019

AUGUST

9

2019

 

August 9th, 2019 – Atlanta, Georgia U.S.A.

Feroz AGAD, Founder, Chairman and Chief Executive of SAH Global and SAH Care appointed to the Advisory Board of Neutron Therapeutics Inc. 

Neutron Therapeutics Inc. (NTI) is a Medical Equipment Company founded in 2005 to bring Boron Neutron Capture Therapy (BNCT) out of the realm of medical research and transform it into a widely available first-line cancer therapy.

NTI has developed an accelerator-based, in-hospital neutron source composed of a 2.6 MeV electrostatic proton accelerator and a rotating, solid lithium target for generating neutrons. NTI will provide this neutron source as part of a comprehensive therapeutic treatment suite, that will combine all of the necessary components for BNCT treatment into a user-friendly package.

BNCT is a unique type of radiation therapy that enables targeting of cancer at the cellular level and treating cancer with a non-invasive two-step process. First, patients are injected with a tumor-seeking drug containing a non-radioactive isotope (boron-10) with a high neutron capture cross-section. In the second step, the patient is exposed to a beam of low energy neutrons, many of which are absorbed by the boron-10. The absorption initiates a reaction that emits short-range, high-energy charged particles. Which systematically destroy the tumor cells while imparting relatively little damage to adjacent areas of healthy tissue.

Feroz AGAD is an accomplished executive, investor and entrepreneur with over 15 years experience of managing multimillion-dollar corporations in industries including healthcare, real estate, communications, tourism and information technology. By capitalizing on his business acumen, technical expertise, interpersonal skills and strategic mindset, Mr. Agad has been instrumental in penetrating new markets and achieving significant sales growth for the companies he has previously founded and managed. Mr. Agad presently sits on the board of directors at four companies and sits on three advisory boards, a committee for a non-profit humanitarian organization and a committee on education.

He established SAH in 2004 with the vision of using the company as a catalyst to bring cutting edge Healthcare technology to the developing world. SAH Global is currently focused on establishing a global network of Proton Therapy Cancer Centers, while SAH Care is the medical treatment abroad division which currently brings cancer patients from around the world to SAH’s network of Cancer Centers for treatment in the USA.

In his overall reach in the fight against cancer, Feroz AGAD has particularly impacted the Industry of Proton Therapy and has demonstrated an exceptional spirit of Innovation to ensure patients from across the world have access to best treatment available. Feroz AGAD defines the future readiness of the Oncology organizations to not only meet the market demand, but to provide compassionate and comprehensive care to patients wherever they live.

With this appointment, NTI will use the experience of Feroz AGAD and of the SAH teams to develop its business, to get the regulatory approvals such as FDA and CE marks, and to conduct the necessary clinical studies to make BNCT available to more of the patients who could benefit from this exciting technique.

 

About SAH Global

Strategic Alliance Holdings Global, LLC (“SAH Global”), is a holding company founded in 2005 to establish highly specialized projects in areas such as healthcare. SAH Global has actively pioneered the effort to bring vital cancer treatment solutions to the Middle East. SAH Global believes in building a strong sustainable society, and as such, will leverage the success of its global ventures to make long-term contributions to the community, promote the growth of their employees, and help create a greener environment.

Read more on https://www.sahglobal.com

About SAH Care

SAH Care was established to ensure that patients from across the world can have access to the best treatments available. We work tirelessly with local physicians and a global network of leading healthcare providers to bring excellent quality cancer care to our patients. Our team, partners, and supporters share a commitment to improve the delivery of high-quality, patient-centric cancer care.
Through travel medicine, we have found a way to provide access to advanced cancer care for those who live in areas where proton therapy centers are yet to be built. We believe that patients deserve to receive the most advanced cancer treatment in the world today despite geographic boundaries and limitations. The SAH Care team provides this compassionate, comprehensive care to patients wherever they live.

Read more on https://www.sahcare.com

About NTI

Neutron Therapeutics is a Boston-area medical equipment company founded in 2015 by New Zealander, Bill Buckley. The mission of NTI is to provide innovative technology solutions that will enable BNCT to realize its maximum potential in the treatment of difficult cancers.

The Neutron Therapeutics neutron source is not approved for commercial or clinical use by the FDA or EMA or other regulatory body.

Read more on https://www.neutrontherapeutics.com

 

NOVEMBER

13 & 14

2018

NOVEMBER

13 & 14

2018

NOVEMBER

08

2018

NOVEMBER

08

2018

NOVEMBER

06

2018

NOVEMBER

06

2018

OCTOBER

25

2018

OCTOBER

25

2018

OCTOBER

13

2018

OCTOBER

13

2018

OCTOBER

11 – 13

2018

OCTOBER

11 – 13

2018

OCT

12

2018

OCT

12

2018

OCT

11

2018

OCT

11

2018

OCT

05

2018

OCT

05

2018

SEPT

29

2018

SEPT

29

2018

SEPTEMBER

24 – 25

2018

SEPTEMBER

24 – 25

2018

SEPT

09

2018

SEPT

09

2018

AUG

27

2018

AUG

27

2018

AUG

20

2018

AUG

20

2018

AUG

17

2018

AUG

17

2018

AUG

05

2018

AUG

05

2018

AUG

02

2018

AUG

02

2018

JULY

31

2018

JULY

31

2018

www.technologynetworks.com Cancer Research UK

JULY

20

2018

JULY

20

2018

JULY

09

2018

JULY

09

2018

JULY

02

2018

JULY

02

2018

JUNE

08

2018

JUNE

08

2018

JUNE

04

2018

JUNE

04

2018

MAY

22

2018

MAY

22

2018

MAY

16

2018

MAY

16

2018

MAY

03

2018

MAY

03

2018

MAY

01

2018

MAY

01

2018

APR

26

2018

APR

26

2018

APR

20

2018

APR

20

2018

JAN

31

2018

JAN

31

2018

JAN

30

2018

JAN

30

2018

JAN

29

2018

JAN

29

2018

SAH Global  Proton Therapy Cancer Centers ensure that patients from across the world can have access to the best treatments available. We work tirelessly with local physicians and a global network of leading healthcare providers to bring excellent quality cancer care to our patients.
Healthcare professionals are invited to meet our Proton Therapy experts on the SAH Global booth during Arab Health, from January 29th to February 1st, Sheikh Saeed Hall 3 S3.C70.
The SAH Team will explain how we currently treat with Proton Therapy.
Professionals can come to SAH booth to discuss cancer cases, have a peer-to-peer review and figure out how Proton Therapy can improve survival chances and quality of life for patients.
SAH will also hold specialized Hands-on-Training sessions :
Module 1 : Clinical indications for Proton Therapy – General 
Module 2 : Clinical benefits of Proton Therapy for Children
Module 3 : Clinical benefits for Brain, Head and Neck, Central Nervous System cancers
Module 4 : Clinical benefits for Re-treatment and Complex cases
Module 5 : Treatment planning: Protons vs photons
Module 6 : Optimizing Patient Outcomes and Workflow Optimization
Module 7 : Bio-Markers and Early Cancer Detection 
Healthcare Professionals are invited to join the SAH Network and to become part of a network of experts that are committed to bringing the latest in cancer treatment options to their patients.

DEC

05

2017

DEC

05

2017

Proton beam therapy (PBT) in children and young adults with nonhematologic malignancies of the head and neck appeared to be safe and delivered local control rates similar to those seen historically.

NOV

14

2017

NOV

14

2017

Proton beam therapy (PBT) may be a better treatment option for pediatric patients with head and neck cancers than first-line therapy with traditional photon radiation, according to a new study published by Pediatric Blood and Cancer. The authors found that PBT results in similar outcomes with less of a detrimental impact on quality of life.
“These data show proton therapy is not only effective, it is also more tolerable for patients,” Dr Hill-Kayser said. “This study shows this treatment is safe and offers practice guidelines for delivering head and neck proton therapy in the pediatric population.”

OCT

29

2017

OCT

29

2017

A single mother from Sydney reveals how ‘Facebook saved her life’ after cancer. In November 2016 she was told she had a rare brain cancer and would die. She found out about proton therapy on social media and went to America for it. The therapy was successful, she has a 95 percent chance of surviving 15 years. The therapy could be available in Sydney as soon as 2020, campaigners say.

OCT

27

2017

OCT

27

2017

Proton therapy may ensure higher survival rates and a decline in complications among prostate cancer patients compared to intensity-modulated radiation therapy (IMRT). 

OCT

27

2017

OCT

27

2017

OCT

19

2017

OCT

19

2017

A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.

SEP

11

2017

SEP

11

2017

AUG

03

2017

AUG

03

2017

Five-year results of a single-institution study show that proton beam radiotherapy given concurrently with chemotherapy offers promising clinical outcomes with good toxicity results compared with historical data.

MAR

21

2017

MAR

21

2017

The use of reirradiation with intensity-modulated proton therapy yielded strong overall survival with limited toxicity in patients with thoracic tumors, potentially offering a new option in this patient population.

MAR

15

2017

MAR

15

2017

In this article we discuss the specifics of refining current strategies for radiation delivery, as well as new and up-and-coming heavy particle techniques and radiotherapeutics.

JUN

2017

JUN

2017

CERN is the world’s largest particle physics research laboratory. Since it was established in 1954, it has made an outstanding contribution to our understanding of the fundamental particles and their interactions, and also to the technologies needed to analyse their properties and behaviour. The experimental challenges have pushed the performance of particle accelerators and detectors to the limits of our technical capabilities, and these groundbreaking technologies can also have a significant impact in applications beyond particle physics. In particular, the detectors developed for particle physics have led to improved techniques for medical imaging, while accelerator technologies lie at the heart of the irradiation methods that are widely used for treating cancer.

Indeed, many important diagnostic and therapeutic techniques used by healthcare professionals are based either on basic physics principles or the technologies developed to carry out physics research. Ever since the discovery of x-rays by Roentgen in 1895, physics has been instrumental in the development of technologies in the biomedical domain, including the use of ionizing radiation for medical imaging and therapy. Some key examples that are explored in detail in this book include scanners based on positron emission tomography, as well as radiation therapy for cancer treatment. Even the collaborative model of particle physics is proving to be effective in catalysing multidisciplinary research for medical applications, ensuring that pioneering physics research is exploited for the benefit of all.

JAN

2017

JAN

2017

Cancer therapy is a multi-modality approach including surgery, systemic or targeted chemotherapy, radiation (external beam or radionuclide), and immunotherapy. Radiation is typically administered using external beam photon therapy. Proton therapy has been around for more than 60 years but was restricted to research laboratories until the 1990s. Since then clinical proton therapy has been growing rapidly with currently more than 50 facilities worldwide. The interest in proton therapy stems from the physical properties of protons allowing for advanced dose sculpting around the target and sparing of healthy tissue. This review first evaluates the basics of proton therapy physics and technology and then outlines some of the current physical, biological, and clinical challenges. Solving these will ultimately determine whether proton therapy will continue on its path to becoming mainstream.

WhatsApp us